Working in a highly collaborative and open effort, scientists have identified 70 virtual compounds to be tested for their capability of inhibiting SARS-CoV2, the virus responsible for COVID-19, hopefully leading to new options for treatment.
Certification effort will leverage Black & Veatch’s COVID-19 services suite as a platform to provide new facility, population health solutions to commercial property, franchise owners and education sites
OVERLAND PARK, Kan., December 8, 2020 /3BL Media/ – There’s a need to forge alliances and working groups to mitigate the COVID-19 pandemic’s impact. Oncor Consulting is among those leading the charge, collaborating with Black & Veatch through their health and safety solutions alliance to deliver a holistic approach to managing population health and creating healthy spaces to work and learn.
ST. PAUL, Minn., November 19, 2020 /3BL Media/ - Ecolab Inc., the global leader in water, hygiene and infection prevention solutions and services, is the first to receive EPA product approval for disinfection of biofilms[i] in wastewater drains for its Virasept™ product – an important part of a comprehensive environmental hygiene program designed to help effectively combat bacterial growth in hospitals.
Virasept (EPA Reg. No. 1677-226) is a patented, peracid mixture, ready-to-use cleaner, deodorizer and hospital disinfectant.
New health-related data is arriving almost daily. Making sense of it all is a huge challenge.
By Huei-Sin Ee
Get ready for a deluge of health data. The market for bedside monitors, remote health trackers, wearable medical apparatus and digital consumer devices is exploding. And that’s not even counting information collected from critical care instruments or paper questionnaires that most patients are still required to fill out prior to an appointment.
Rethinking best practices for the design and operation of health care facilities in light of the COVID-19 pandemic
Dominick DeRobertis joined Tetra Tech’s High Performance Buildings Group in 2000, becoming a senior vice president and director of health care in 2007. He has more than 25 years of experience in a wide variety of project types, including hospitals, educational facilities, museums, office buildings, hotels, residential buildings, tenant interiors, and retail.
What if healthcare innovations could heal beyond the hospital and change communities?
In fiscal year 2020 (FY20), we were powered by our purpose—proving that an enduring Mission can inspire new thinking and innovative ways to alleviate pain, restore health, and extend lives.
In the last year, we invested $2.3 billion in research and development and ran more than 270 clinical studies to engineer and test meaningful innovations that will make a difference to patients and healthcare systems globally. Our investment fuels a product pipeline that impacts more than two patients every second.
CRB report explores challenges and solutions as cell and gene therapy organizations confront new urgency for patient therapies
KANSAS CITY, Mo., Oct. 28, 2020 /3BL Media/ – From the global COVID-19 pandemic to rare and challenging health threats, our world seems forever on the defense against disease and in need of a nimble and efficient vaccine and therapy supply chain. But a new report from CRB, a leading global provider of biopharma manufacturing solutions, spotlights the critical conflicts threatening the speedy delivery of patient therapies.